In this study we tested whether BRAF and/or TERT promoter mutations conferred sensitivity to YK-4-279 in thyroid cancer cells and whether this inhibitor could be served as a therapeutic agent for advanced thyroid cancers. This evidence concerns the gene BRAF and thyroid gland carcinoma.